ArticleBMC pediatrics2025
Burden of bronchiolitis post-COVID-19 pandemic in children less than 2 years old in 2021-2024: experience from a tertiary center in Saudi Arabia.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Invasive Pneumococcal Diseases Before and After the COVID-19 Pandemic in Italy (2018-2023).Microorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBronchiolitis, a common lower respiratory tract infection in children under 2, is primarily caused by respiratory syncytial virus (RSV). During the coronavirus disease (COVID-19) pandemic, respiratory infections initially decreased due to non-pharmaceutical interventions; however, patients with bronchiolitis have surged in the post-pandemic period. This study examined the burden and severity of bronchiolitis in the post-COVID era in a tertiary center in Saudi Arabia.
methodsThis retrospective review was conducted on pediatric patients aged < 2 years who were diagnosed with bronchiolitis at a tertiary hospital in Riyadh between September 2021 and March 2024. The collected data included demographics, comorbidities, viral polymerase chain reaction results, clinical management, disposition, and outcomes. Statistical analysis was performed using SPSS, with statistical significance at p < 0.05.
resultsOut of 482 patients, 56% were male, with a mean age of 6.37 months. RSV was the most common virus (53.79%) among the 132 tested patients. Oxygen therapy was administered to 93.15% of patients, with only 4.36% requiring high-flow nasal cannula and 0.41% requiring intubation. Pediatric Intensive Care Unit admission was necessary for 5.6%, with most managed with non-invasive support. Complications were infrequent; only 4.77% developed pneumonia.
conclusionsThe findings reflect a significant increase in patients with bronchiolitis post-COVID, consistent with the global trends. Despite this increase, most patients required minimal intervention, aligning with pre-pandemic management practices. This study highlighted the post-pandemic resurgence of bronchiolitis. While the caseload has increased, outcomes remain favorable, reinforcing the importance of supportive care and judicious resource allocation during the bronchiolitis season.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.